tiprankstipranks
Kohjin Bio Co.,Ltd. (JP:177A)
:177A
Japanese Market
Want to see JP:177A full AI Analyst Report?

Kohjin Bio Co.,Ltd. (177A) Price & Analysis

0 Followers

177A Stock Chart & Stats

¥1525.00
-¥17.00(-1.03%)
At close: 4:00 PM EST
¥1525.00
-¥17.00(-1.03%)

Bulls Say, Bears Say

Bulls Say
Improving LeverageA lower debt-to-equity ratio reduces refinancing and interest-rate vulnerability and increases financial flexibility. This improving leverage profile supports durable capital allocation for R&D, partnerships or M&A and lowers the risk of balance-sheet stress over the next 2–6 months.
Stronger Equity BaseA materially larger equity base provides a cushion against earnings volatility and reduces reliance on short-term borrowings. That strengthens the firm's ability to fund clinical development and investment without immediate external financing, improving resilience over the medium term.
Historical Margin CapabilityPrior periods of strong margins indicate the underlying business model can achieve attractive profitability through pricing or cost structure. This historical capability supports the prospect of margin recovery if revenue stabilizes, implying durable operational leverage.
Bears Say
Revenue DeclineA YoY revenue decline signals weakening demand or possible market share erosion. Sustained top-line contraction undermines scale economics and jeopardizes funding for R&D and commercialization, making it harder to restore prior growth and profitability over the medium term.
Margin CompressionSharp margin deterioration materially cuts internal cash generation and return on equity. If driven by structural cost increases or pricing pressure, compressed margins will limit reinvestment capacity and make sustaining prior profitability levels difficult absent strategic changes.
Negative Free Cash Flow / Cash ConversionNegative and volatile free cash flow undermines the firm’s ability to self-fund operations and invest. Repeated poor cash conversion increases reliance on external financing or asset sales, raising execution risk and potentially constraining strategic initiatives over the coming months.

177A FAQ

What was Kohjin Bio Co.,Ltd.’s price range in the past 12 months?
Kohjin Bio Co.,Ltd. lowest stock price was ¥961.00 and its highest was ¥2020.00 in the past 12 months.
    What is Kohjin Bio Co.,Ltd.’s market cap?
    Kohjin Bio Co.,Ltd.’s market cap is ¥5.48B.
      When is Kohjin Bio Co.,Ltd.’s upcoming earnings report date?
      Kohjin Bio Co.,Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 61 days.
        How were Kohjin Bio Co.,Ltd.’s earnings last quarter?
        Kohjin Bio Co.,Ltd. released its earnings results on May 15, 2026. The company reported -¥5.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.6.
          Is Kohjin Bio Co.,Ltd. overvalued?
          According to Wall Street analysts Kohjin Bio Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kohjin Bio Co.,Ltd. pay dividends?
            Kohjin Bio Co.,Ltd. pays a Notavailable dividend of ¥9.922 which represents an annual dividend yield of 1.62%. See more information on Kohjin Bio Co.,Ltd. dividends here
              What is Kohjin Bio Co.,Ltd.’s EPS estimate?
              Kohjin Bio Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Kohjin Bio Co.,Ltd. have?
              Kohjin Bio Co.,Ltd. has 5,111,600 shares outstanding.
                What happened to Kohjin Bio Co.,Ltd.’s price movement after its last earnings report?
                Kohjin Bio Co.,Ltd. reported an EPS of -¥5.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.838%.
                  Which hedge fund is a major shareholder of Kohjin Bio Co.,Ltd.?
                  Currently, no hedge funds are holding shares in JP:177A
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Kohjin Bio Co.,Ltd.

                    Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.

                    Kohjin Bio Co.,Ltd. (177A) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    StemRIM Inc.
                    Takara Bio Inc.
                    ReproCELL Inc.
                    Japan Tissue Engineering Co., Ltd.
                    CellSeed Inc.
                    Popular Stocks